Sarcoma / 2013 / Article / Fig 2

Clinical Study

Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma

Figure 2

Median OS: 11.2 months (95% CI: 5.7–16.7). OS rate at 1 year: 39.6%. Median followup: 11.8 months.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.